SEC Form 10-K filed by Halozyme Therapeutics Inc.
$HALO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2025 | $62.00 | Overweight → Equal-Weight | Morgan Stanley |
| 5/13/2025 | $47.00 | Market Perform → Underperform | Leerink Partners |
| 10/7/2024 | $58.00 → $62.00 | Overweight → Equal Weight | Wells Fargo |
| 9/19/2024 | $52.00 → $57.00 | Overweight → Neutral | JP Morgan |
| 6/7/2024 | $48.00 → $51.00 | Overweight → Neutral | Piper Sandler |
| 2/29/2024 | $54.00 | Outperform | TD Cowen |
| 7/24/2023 | $61.00 | Buy | H.C. Wainwright |
| 7/24/2023 | $43.00 → $45.00 | Buy → Neutral | Goldman |
SCHEDULE 13G - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)